The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
BUSINESS
FDA Approves Astellas’ Blockbuster Hopeful for Hot Flash Treatment
Astellas Pharma said on May 13 that the US FDA has granted approval for its nonhormonal drug Veozah (fezolinetant) for the treatment of moderate to severe vasomotor symptoms (VMS) due to menopause, known as hot flashes or night sweats. While…
To read the full story
Related Article
- Astellas’ Hot Flash Drug Bags European Nod
December 12, 2023
- EU Panel Backs Astellas’ Hot Flash Drug
October 17, 2023
- Astellas’ Hot Flash Med Nets Positive PIIIb Results in Europe
June 29, 2023
- Astellas CEO Confident about Veozah Uptake, 500 Billion Yen Sales Potential
May 22, 2023
- FDA Target Date for Hot Flash Med Extended by 3 Months: Astellas
February 21, 2023
- EMA Accepts Astellas’ Hot Flash Drug for Review
October 3, 2022
- Astellas’ Hot Flash Med Accepted by FDA Review, Gets Short-Cut with Voucher Use
August 19, 2022
- Astellas’ Vasomotor Symptom Med Missed Primary Goal in Asian PIII Study
March 16, 2022
- Astellas’s Hot Flash Drug Fezolinetant Delivers Positive PIII Data
March 8, 2022
- Astellas’ Hot Flash Drug Hits Primary Goals in PIII Studies
February 22, 2021
BUSINESS
- Kyowa Kirin’s New Skipper Sees Further Growth Overseas, Vows to Cherish People
May 1, 2025
- Kyowa Kirin CEO Will Now Focus on Strategic Matters and External Dialogue
May 1, 2025
- Japan Pharma Sales Creep Up to 10.8 Trillion in FY2024: Encise
May 1, 2025
- Paxlovid Filed for Pediatric Label Expansion in Japan: Pfizer
May 1, 2025
- Moderna Taps Asia Chief as Japan Representative Director, Marketing Head as GM
April 28, 2025
Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…